Co-packaging of Adalat(R) XL(R) and ASPIRIN(R) 81mg Now Available in
TORONTO, Aug. 12 /CNW/ - Bayer Inc. announced that Health Canada has
granted a Notice of Compliance (NOC) for Adalat(R) XL(R) PLUS, a co-packaging
of Adalat(R) XL(R) and ASPIRIN(R) 81mg.
Adalat(R) XL(R) PLUS (nifedipine extended-release tablets and
acetylsalicylic acid delayed-release tablets) is indicated for patients for
whom treatment with both Adalat(R) XL(R) and ASPIRIN(R) 81mg is appropriate.
Adalat(R) XL(R) PLUS is not indicated for initial therapy. The dose of
nifedipine should be determined by titration before the switch to Adalat(R)
XL(R) PLUS. Once the dose of nifedipine has been established, patients should
take one tablet of Adalat(R) XL(R) (nifedipine extended-release tablets) and
one tablet of ASPIRIN(R) 81mg (acetylsalicylic acid delayed-release tablets)
"Hypertension is a significant risk factor for cardiovascular events,"
said Dr. Akbar Panju, Professor of Medicine and Vice Chair (Clinical) at
McMaster University and former Chief of Medicine at Hamilton Health Sciences.
"Packaging Adalat(R) XL(R) and ASPIRIN(R) 81mg together offers patients the
convenience of receiving the daily preventative therapy as well as the
antihypertensive benefits of Adalat(R) XL(R)."
"As a leader in cardiovascular care, Bayer is committed to providing
solutions that will help to improve the cardiovascular health of Canadians,"
said Philip Blake, President and CEO, Bayer Inc. "The release of Adalat(R)
XL(R) PLUS responds directly to patients' needs by improving ease of use,
enabling better patient compliance and, most important, resulting in better
Adalat(R) XL(R), an antianginal and antihypertensive, received its
initial NOC in 1992, and is indicated for the treatment of chronic stable
angina and mild to moderate hypertension. ASPIRIN(R) received NOC for a
low-dose 81-mg formulation in 1998 for use as a physician-supervised daily
Hypertension and Associated Risks
In Canada, hypertension results in more patient visits to a physician
than any other diagnosis, with over 20 million visits per year.(4)
Hypertension is a risk factor for cerebrovascular disease, coronary artery
disease, congestive heart failure, renal failure, peripheral vascular disease,
dementia and atrial fibrillation. It has been shown that 90 per cent of
hypertensive Canadians have additional cardiovascular risk factors.(5)
Patient Preference Study
According to a survey of Canadian patients taking both Adalat(R) XL(R)
and low dose acetylsalicylic acid (ASA), 93 per cent of patients indicated a
preference for a dual prescription of Adalat(R) XL(R) and ASA and 80 per cent
indicated they would take their medication more regularly if offered in this
Dosage and Packaging of Adalat(R) XL(R) PLUS
Adalat(R) XL(R) PLUS is available in cartons containing 28 ASPIRIN(R) 81
mg tablets packed with 28 (either 20 mg, 30 mg, or 60 mg) Adalat(R) XL(R)
tablets. The tablets are packaged in clear blisters and are arranged side by
side. Due to the clear nature of the blister package and the difference in
colour of the two products, they are readily distinguishable from each
About Bayer Inc
Bayer Inc. (Bayer) is a Canadian subsidiary of Bayer AG, an international
research-based group with core businesses in health care, crop science, and
Headquartered in Toronto, Ontario, Bayer Inc. operates the Bayer Group's
HealthCare and MaterialScience businesses in Canada. Bayer Crop Science Inc.,
headquartered in Calgary, Alberta operates as a separate legal entity in
Canada. Together, the companies play a vital role in improving the quality of
life for Canadians - producing products that fight diseases, protecting crops
and animals, and developing high-performance materials for applications in
numerous areas of daily life. Canadian Bayer facilities include the Toronto
headquarters and offices in Ottawa and Calgary.
Bayer Inc. has approximately 1,000 employees across Canada and had sales
of over $986 million CDN in 2007. Globally, the Bayer Group had sales of over
32 billion Euro in 2007. Bayer Inc. invested approximately $45 million CDN in
research and development in 2007. Worldwide, the Bayer Group spends the
equivalent of over 2.5 billion Euro in 2007 in R&D.
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer's public reports which are available
on the Bayer website at www.bayer.com. The company assumes no liability
whatsoever to update these forward-looking statements or to conform them to
future events or developments.
1. Adalat(R) XL(R) PLUS product monograph. Bayer Inc. 2008.
2. Adalat(R) XL(R) product monograph. Bayer Inc. 2008
3. Aspirin(R) product monograph. Bayer Inc. 2008
4. IMS HEALTH Canada 2002. http://www.imshealthcanada.com/
5. 2008 Canadian Hypertension Education Program background slides.
6. 2008 Canadian Hypertension Education Program Recommendations for the
Management of Hypertension.
7. Eidelman R, et al. An Update on Aspirin in Primary Prevention of
Cardiovascular Disease. Ann Intern Med 2003;163:2006-10.
8. Bayer HealthCare Patient Preference Program. Bayer Inc. 2008.
For further information:
For further information: Veritas Communications, Karl Baldauf, (416)
955-4574, Baldauf@veritascanada.com; Bayer Inc., Emily Hanft, (416) 240-5434,